Univariate and multivariate models of factors associated with PFS after treatment of PMBCL (N = 65)
| Variable . | Univariate . | Multivariate model 1 . | Multivariate model 2 . | |||
|---|---|---|---|---|---|---|
| HR (95% CI) . | P . | HR (95% CI) . | P . | HR (95% CI) . | P . | |
| Pre–DA-R-EPOCH | ||||||
| Age | 0.977 (0.923-1.033) | .407 | ||||
| Female | 0.417 (0.125-1.386) | .154 | ||||
| B symptoms | 0.926 (0.251-3.419) | .908 | ||||
| Bulky disease (>10 cm) | 6.17 (0.80-47.81) | .082 | 2.107 (0.233-19.042) | .507 | 1.282 (0.080-20.494) | .861 |
| IPI score (0-1 vs 2) | 1.304 (0.286-5.954) | .732 | ||||
| MTVhigh | 11.528 (1.486-89.442) | .019 | 8.345 (0.924-75.387) | .059 | ||
| TLGhigh | 8.989 (1.96-41.228) | .005 | 7.879 (1.005-61.754) | .049 | ||
| BIC | 95.5 | 94.8 | ||||
| Post–DA-R-EPOCH | ||||||
| CT residualhigh | 5.974 (1.61-22.117) | .007 | 1.530 (0.413-5.673) | .525 | 1.861 (0.311-11.14) | .496 |
| Posttreatment SUVmax high | 49.45 (6.334-386.037) | .00019 | ||||
| Deauville 1-3 vs 4-5 | 187.329 (0.874-40 150.184) | .056 | 1.7 × 105 (0-2.0 × 1082) | .894 | ||
| Deauville 1-4 vs 5 | 14.442 (4.418 – 47.209) | .00001 | 9.525 (1.928-47.066) | .006 | ||
| BIC | 78.7 | 88.0 | ||||
| Pre– and Post–DA-R-EPOCH | ||||||
| TLGhigh | 5.046 (1.016-25.053) | .048 | 2.703 (0.588-12.422) | .201 | ||
| Deauville 1-3 vs 4-5 | 1.3 × 105 (0-8.2 × 1081) | .896 | ||||
| Deauville 1-4 vs 5 | 8.578 (2.470-29.798) | .001 | ||||
| BIC | 83.6 | 77.2 | ||||
| Variable . | Univariate . | Multivariate model 1 . | Multivariate model 2 . | |||
|---|---|---|---|---|---|---|
| HR (95% CI) . | P . | HR (95% CI) . | P . | HR (95% CI) . | P . | |
| Pre–DA-R-EPOCH | ||||||
| Age | 0.977 (0.923-1.033) | .407 | ||||
| Female | 0.417 (0.125-1.386) | .154 | ||||
| B symptoms | 0.926 (0.251-3.419) | .908 | ||||
| Bulky disease (>10 cm) | 6.17 (0.80-47.81) | .082 | 2.107 (0.233-19.042) | .507 | 1.282 (0.080-20.494) | .861 |
| IPI score (0-1 vs 2) | 1.304 (0.286-5.954) | .732 | ||||
| MTVhigh | 11.528 (1.486-89.442) | .019 | 8.345 (0.924-75.387) | .059 | ||
| TLGhigh | 8.989 (1.96-41.228) | .005 | 7.879 (1.005-61.754) | .049 | ||
| BIC | 95.5 | 94.8 | ||||
| Post–DA-R-EPOCH | ||||||
| CT residualhigh | 5.974 (1.61-22.117) | .007 | 1.530 (0.413-5.673) | .525 | 1.861 (0.311-11.14) | .496 |
| Posttreatment SUVmax high | 49.45 (6.334-386.037) | .00019 | ||||
| Deauville 1-3 vs 4-5 | 187.329 (0.874-40 150.184) | .056 | 1.7 × 105 (0-2.0 × 1082) | .894 | ||
| Deauville 1-4 vs 5 | 14.442 (4.418 – 47.209) | .00001 | 9.525 (1.928-47.066) | .006 | ||
| BIC | 78.7 | 88.0 | ||||
| Pre– and Post–DA-R-EPOCH | ||||||
| TLGhigh | 5.046 (1.016-25.053) | .048 | 2.703 (0.588-12.422) | .201 | ||
| Deauville 1-3 vs 4-5 | 1.3 × 105 (0-8.2 × 1081) | .896 | ||||
| Deauville 1-4 vs 5 | 8.578 (2.470-29.798) | .001 | ||||
| BIC | 83.6 | 77.2 | ||||